1
|
Wang X, Wang M, Shen Y. Higher systemic inflammation response index is associated with increased risk of heart failure in adults: An observational study. Medicine (Baltimore) 2024; 103:e38625. [PMID: 38996176 DOI: 10.1097/md.0000000000038625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 07/14/2024] Open
Abstract
Inflammation has been established to play a crucial role in the onset of heart failure (HF) for many years, and the systemic inflammation response index (SIRI) is a new and comprehensive indicator reflecting the inflammation status in human body. The aim of this investigation was to determine the potential relationship between HF and SIRI in adults. For this investigation, we used cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), which was conducted from 2009 to 2018. The study utilized multivariable linear regression models to examine the potential independent relationship between HF and SIRI. Additionally, a subgroup analysis and interaction test were carried out. To illustrate the nonlinear relationship, threshold effect analysis and fitted smoothing curves were also used. 26,303 eligible subjects aged ≥ 20 years were enrolled as the final samples. HF participants exhibited significant higher SIRI compared with non-HF participants [1.89 ± 1.33 vs 1.25 ± 0.95 (1000 cells/μL), P < .0001]. Multivariate logistic regression showed that those in the highest SIRI quartile had a significantly greater risk of HF by 130% (OR = 2.30, 95% CI 1.41-3.76; P < .0001). In addition, nonlinear relationship between HF and SIRI with the inflection point of 2.2 (1000 cells/μL) was observed. According to our research, adult HF prevalence and SIRI are positively correlated. This implies that SIRI could be a valuable biomarker for determining HF risk in the clinic.
Collapse
Affiliation(s)
- Xiao Wang
- Department of Oncology, Affiliated Hospital of Panzhihua University, Panzhihua, Sichuan, China
| | - Min Wang
- Department of Endocrinology, Sichuan Taikang Hospital, Chengdu, Sichuan, China
| | - Yishi Shen
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
| |
Collapse
|
2
|
van Zwol W, van de Sluis B, Ginsberg HN, Kuivenhoven JA. VLDL Biogenesis and Secretion: It Takes a Village. Circ Res 2024; 134:226-244. [PMID: 38236950 DOI: 10.1161/circresaha.123.323284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Accepted: 09/21/2023] [Indexed: 01/23/2024]
Abstract
The production and secretion of VLDLs (very-low-density lipoproteins) by hepatocytes has a direct impact on liver fat content, as well as the concentrations of cholesterol and triglycerides in the circulation and thus affects both liver and cardiovascular health, respectively. Importantly, insulin resistance, excess caloric intake, and lack of physical activity are associated with overproduction of VLDL, hepatic steatosis, and increased plasma levels of atherogenic lipoproteins. Cholesterol and triglycerides in remnant particles generated by VLDL lipolysis are risk factors for atherosclerotic cardiovascular disease and have garnered increasing attention over the last few decades. Presently, however, increased risk of atherosclerosis is not the only concern when considering today's cardiometabolic patients, as they often also experience hepatic steatosis, a prevalent disorder that can progress to steatohepatitis and cirrhosis. This duality of metabolic risk highlights the importance of understanding the molecular regulation of the biogenesis of VLDL, the lipoprotein that transports triglycerides and cholesterol out of the liver. Fortunately, there has been a resurgence of interest in the intracellular assembly, trafficking, degradation, and secretion of VLDL by hepatocytes, which has led to many exciting new molecular insights that are the topic of this review. Increasing our understanding of the biology of this pathway will aid to the identification of novel therapeutic targets to improve both the cardiovascular and the hepatic health of cardiometabolic patients. This review focuses, for the first time, on this duality.
Collapse
Affiliation(s)
- Willemien van Zwol
- Department of Paediatrics, University Medical Center Groningen, University of Groningen, the Netherlands (W.v.Z., B.v.d.S., J.A.K.)
| | - Bart van de Sluis
- Department of Paediatrics, University Medical Center Groningen, University of Groningen, the Netherlands (W.v.Z., B.v.d.S., J.A.K.)
| | - Henry N Ginsberg
- Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY (H.N.G.)
| | - Jan Albert Kuivenhoven
- Department of Paediatrics, University Medical Center Groningen, University of Groningen, the Netherlands (W.v.Z., B.v.d.S., J.A.K.)
| |
Collapse
|
3
|
Lin S, Huang S, Deng Z, Zhang Y, Huang L, Wu Y, Lv S, Wang Z, Huang N, Wang L, Chen Z, Yu G, Yin W, Zhou Y, Fang Z. Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders. Front Endocrinol (Lausanne) 2023; 14:1109615. [PMID: 36742393 PMCID: PMC9896003 DOI: 10.3389/fendo.2023.1109615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 01/09/2023] [Indexed: 01/21/2023] Open
Abstract
INTRODUCTION Thyroid hormone receptor β (THR-β) plays a critical role in metabolism regulation and has become an attractive target for treating lipid metabolism disorders in recent years. Thus, in this study, we discovered CS271011, a novel THR-β agonist, and assessed the safety and efficiency of CS271011 compared to MGL-3196 in vitro and in vivo. METHODS We conducted luciferase reporter gene assays to assess the activation of THR-β and α in vitro. C57BL/6J mice were fed a high-fat diet for 12 weeks, CS271011 was administered by gavage at the dose of 1 mg/kg and 3 mg/kg, and MGL-3196 was administered at the dose of 3 mg/kg for 10 weeks. Body weight, food intake, serum and hepatic parameters, histological analysis, pharmacokinetic studies, RNA sequencing of the liver and heart, and expression of hepatic lipid-metabolic genes were determined to evaluate the safety and efficiency of CS271011. RESULTS Compared with MGL-3196, CS271011 showed higher THR-β activation in vitro. In the diet-induced obesity mice model, CS271011 demonstrated favourable pharmacokinetic properties in mice and was enriched in the liver. Finally, CS271011 improved dyslipidaemia and reduced liver steatosis in the diet-induced obesity murine model. Mechanistically, CS271011 and MGL-3196 showed potent regulation of lipid metabolism-related genes. CONCLUSIONS CS271011 is a potent and liver-targeted THR-β agonist for treating lipid metabolism disorders.
Collapse
Affiliation(s)
- Suwen Lin
- Clinical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, China
| | - Shengjian Huang
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
- Chengdu Chipscreen Pharmaceutical Ltd., Chengdu, Sichuan, China
| | - Zhou Deng
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
| | - Yu Zhang
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
| | - Lin Huang
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
| | - Yanyi Wu
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
| | - Shuyan Lv
- Clinical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, China
| | - Zhiyi Wang
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
| | - Ning Huang
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
| | - Lan Wang
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
| | - Ziqi Chen
- School of Chemical Engineering and Technology, Hainan University, Haikou, Hainan, China
| | - Guangyin Yu
- Department of Pathology, Shenzhen Hospital, Peking University, Shenzhen, Guangdong, China
| | - Weihua Yin
- Department of Pathology, Shenzhen Hospital, Peking University, Shenzhen, Guangdong, China
| | - You Zhou
- Early Research & Development Centers, Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, Guangdong, China
- *Correspondence: You Zhou, ; Zhengyu Fang,
| | - Zhengyu Fang
- Clinical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, Guangdong, China
- Department of Pathology, Shenzhen Hospital, Peking University, Shenzhen, Guangdong, China
- *Correspondence: You Zhou, ; Zhengyu Fang,
| |
Collapse
|